ImmunoVaccine Company Profile (CVE:IMV)

About ImmunoVaccine (CVE:IMV)

ImmunoVaccine logoImmunovaccine Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company’s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus. The company has research collaborations with companies and research organizations, including Merck KGaA, Incyte Corporation, and Leidos Inc, as well as with Zoetis. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: CVE:IMV
  • CUSIP: N/A
  • Web:
  • Market Cap: C$173.67 million
  • Outstanding Shares: 127,701,000
Average Prices:
  • 50 Day Moving Avg: C$1.18
  • 200 Day Moving Avg: C$1.24
  • 52 Week Range: C$0.65 - C$1.70
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: C$0.10 per share
  • Price / Book: 13.60
  • EBITDA: ($8,480,000.00)
  • Average Volume: 99,941 shs.
  • Short Ratio: 0.48

Frequently Asked Questions for ImmunoVaccine (CVE:IMV)

What is ImmunoVaccine's stock symbol?

ImmunoVaccine trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IMV."

When will ImmunoVaccine make its next earnings announcement?

ImmunoVaccine is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for ImmunoVaccine.

Where is ImmunoVaccine's stock going? Where will ImmunoVaccine's stock price be in 2017?

0 equities research analysts have issued 1-year target prices for ImmunoVaccine's stock. Their forecasts range from C$1.70 to C$1.70. On average, they anticipate ImmunoVaccine's stock price to reach C$1.70 in the next twelve months. View Analyst Ratings for ImmunoVaccine.

Who are some of ImmunoVaccine's key competitors?

How do I buy ImmunoVaccine stock?

Shares of ImmunoVaccine and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ImmunoVaccine's stock price today?

One share of ImmunoVaccine stock can currently be purchased for approximately C$1.36.

MarketBeat Community Rating for ImmunoVaccine (CVE IMV)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about ImmunoVaccine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmunoVaccine (CVE:IMV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: C$1.70
Consensus Price Target History for ImmunoVaccine (CVE:IMV)
Price Target History for ImmunoVaccine (CVE:IMV)
Analysts' Ratings History for ImmunoVaccine (CVE:IMV)
DateFirmActionRatingPrice TargetDetails
12/16/2016MackieLower Price TargetC$1.85 -> C$1.70View Rating Details
(Data available from 10/22/2015 forward)


Earnings History for ImmunoVaccine (CVE:IMV)
No earnings announcements for this company have been tracked by


Earnings Estimates for ImmunoVaccine (CVE:IMV)
Current Year EPS Consensus Estimate: $-0.08 EPS


Dividend History for ImmunoVaccine (CVE:IMV)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ImmunoVaccine (CVE:IMV)
No insider trades for this company have been tracked by


Headline Trends for ImmunoVaccine (CVE:IMV)
Latest Headlines for ImmunoVaccine (CVE:IMV)
Loading headlines, please wait.



ImmunoVaccine (IMV) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.